- Report
- January 2022
- 60 Pages
Global
From €3551EUR$3,950USD£3,045GBP
- Report
- July 2025
- 350 Pages
Global
From €4450EUR$4,949USD£3,814GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2508EUR$2,789USD£2,150GBP
- Report
- June 2025
- 400 Pages
Global
From €4450EUR$4,949USD£3,814GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4451EUR$4,950USD£3,815GBP
- Report
- May 2024
- 137 Pages
Global
From €2696EUR$2,999USD£2,312GBP
€3596EUR$3,999USD£3,082GBP
- Report
- May 2024
- 135 Pages
Global
From €2696EUR$2,999USD£2,312GBP
€3596EUR$3,999USD£3,082GBP
- Report
- April 2025
- 192 Pages
Global
From €4491EUR$4,995USD£3,850GBP
- Report
- May 2023
- 260 Pages
Global
From €2383EUR$2,650USD£2,043GBP
- Report
- November 2023
- 109 Pages
Global
From €3500EUR$4,170USD£3,105GBP
- Report
- November 2025
- 132 Pages
Global
From €854EUR$950USD£732GBP
The Urinary Incontinence Drug market is a subset of the Urological Disorders Drugs market, which includes drugs used to treat a variety of conditions related to the urinary system. Urinary Incontinence Drugs are used to treat the involuntary leakage of urine, which can be caused by a variety of conditions, including overactive bladder, stress incontinence, and urge incontinence. These drugs can be administered orally, topically, or through injections. Commonly used drugs include anticholinergics, beta-3 agonists, and alpha-blockers.
Some of the companies in the Urinary Incontinence Drug market include Allergan, Astellas Pharma, Pfizer, Merck, and Sanofi. Show Less Read more